IBTROZI

Product NDC
84651-200
11-digit product format
846510200
Labeler code
84651
Product ID
84651-200_12274fa4-44f0-4e87-9683-67b1515ea180
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
taletrectinib
Dosage form
CAPSULE
Route
ORAL
Labeler
Nuvation Bio Inc.
Application
NDA219713
Marketing category
NDA
Marketing start
2025-06-11
Substance
TALETRECTINIB ADIPATE
Active strength
272 mg/1
Pharmacologic classes
Kinase Inhibitor [EPC], Proto-Oncogene Tyrosine-Protein Kinase ROS1 Inhibitors [MoA]
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N219713-001IBTROZITALETRECTINIB ADIPATEEQ 200MG BASECAPSULE / ORALRLD, RS2025-06-11

Orange Book patents#

Current patent rows page 1 of 1 · 2 matching rows.

Application-product, Patent, Expiration table
Application-productPatentExpirationUse codeCoverage / statusSubmission date
N219713-00191874892033-06-03U-4207Drug substance, Drug product2025-06-27
N219713-00197518872033-06-03U-4207Drug substance, Drug product2025-06-27

Orange Book exclusivity#

Current exclusivity rows page 1 of 1 · 2 matching rows.

Application-product, Exclusivity code, Expiration table
Application-productExclusivity codeExpiration
N219713-001NCE2030-06-11
N219713-001ODE-5442032-06-11

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N219713-001IBTROZIEQ 200MG BASECAPSULE / ORALRLD, RS2025-06-11d4dbc9d85df4…
2026-10-15 13:18:302026-09N219713-001IBTROZIEQ 200MG BASECAPSULE / ORALRLD, RS2025-06-11c2088c7a36db…
2026-09-14 22:38:342026-08N219713-001IBTROZIEQ 200MG BASECAPSULE / ORALRLD, RS2025-06-1184e616aacf4f…
2026-08-18 06:07:402026-07N219713-001IBTROZIEQ 200MG BASECAPSULE / ORALRLD, RS2025-06-11caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N219713-001IBTROZIEQ 200MG BASECAPSULE / ORALRLD, RS2025-06-11011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N219713-001IBTROZIEQ 200MG BASECAPSULE / ORALRLD, RS2025-06-1131067a03dcf5…
2025-08-23 18:47 UTC2025-08N219713-001IBTROZIEQ 200MG BASECAPSULE / ORALRLD, RS2025-06-116a471c1ec25d…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N219713-001IBTROZIEQ 200MG BASECAPSULE / ORALRLD, RS2025-06-11a50c72e98297…

Observed Orange Book patent history#

Captured, Edition, Application-product table
CapturedEditionApplication-productPatentExpirationUse codeCoverage / statusSubmission dateSource SHA-256
2026-11-14 07:37:172026-10N219713-00191874892033-06-03U-4207Drug substance, Drug product2025-06-27d4dbc9d85df4…
2026-11-14 07:37:172026-10N219713-00197518872033-06-03U-4207Drug substance, Drug product2025-06-27d4dbc9d85df4…
2026-10-15 13:18:302026-09N219713-00191874892033-06-03U-4207Drug substance, Drug product2025-06-27c2088c7a36db…
2026-10-15 13:18:302026-09N219713-00197518872033-06-03U-4207Drug substance, Drug product2025-06-27c2088c7a36db…
2026-09-14 22:38:342026-08N219713-00191874892033-06-03U-4207Drug substance, Drug product2025-06-2784e616aacf4f…
2026-09-14 22:38:342026-08N219713-00197518872033-06-03U-4207Drug substance, Drug product2025-06-2784e616aacf4f…
2026-08-18 06:07:402026-07N219713-00191874892033-06-03U-4207Drug substance, Drug product2025-06-27caaa826d4ba7…
2026-08-18 06:07:402026-07N219713-00197518872033-06-03U-4207Drug substance, Drug product2025-06-27caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N219713-00191874892033-06-03U-4207Drug substance, Drug product2025-06-27011fe1cb6892…
2026-02-19 14:30 UTC2026-02N219713-00197518872033-06-03U-4207Drug substance, Drug product2025-06-27011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N219713-00191874892033-06-03U-4207Drug substance, Drug product2025-06-2731067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N219713-00197518872033-06-03U-4207Drug substance, Drug product2025-06-2731067a03dcf5…
2025-08-23 18:47 UTC2025-08N219713-00191874892033-06-03U-4207Drug substance, Drug product2025-06-276a471c1ec25d…
2025-08-23 18:47 UTC2025-08N219713-00197518872033-06-03U-4207Drug substance, Drug product2025-06-276a471c1ec25d…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N219713-00191874892033-06-03U-4207Drug substance, Drug product2025-06-27a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N219713-00197518872033-06-03U-4207Drug substance, Drug product2025-06-27a50c72e98297…

Observed Orange Book exclusivity history#

Captured, Edition, Application-product table
CapturedEditionApplication-productExclusivity codeExpirationSource SHA-256
2026-11-14 07:37:172026-10N219713-001NCE2030-06-11d4dbc9d85df4…
2026-11-14 07:37:172026-10N219713-001ODE-5442032-06-11d4dbc9d85df4…
2026-10-15 13:18:302026-09N219713-001NCE2030-06-11c2088c7a36db…
2026-10-15 13:18:302026-09N219713-001ODE-5442032-06-11c2088c7a36db…
2026-09-14 22:38:342026-08N219713-001NCE2030-06-1184e616aacf4f…
2026-09-14 22:38:342026-08N219713-001ODE-5442032-06-1184e616aacf4f…
2026-08-18 06:07:402026-07N219713-001NCE2030-06-11caaa826d4ba7…
2026-08-18 06:07:402026-07N219713-001ODE-5442032-06-11caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N219713-001NCE2030-06-11011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N219713-001NCE2030-06-1131067a03dcf5…
2025-08-23 18:47 UTC2025-08N219713-001NCE2030-06-116a471c1ec25d…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N219713-001NCE2030-06-11a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N219713-001ODE-5442032-06-11a50c72e98297…

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

Additional Listing Data#

Finished product
Yes
Brand name base
IBTROZI
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
TALETRECTINIB ADIPATE272 mg/1

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
6KLL51GNBGInternal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 2 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
2716925Internal RxNorm lookup
2716931Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
51ac8e52-3269-4102-8dc8-dba22d82128cAvailable on FDA.report

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
a62a50ac-1535-4461-9768-8ae703e2e9fbProduct name120210525
9514609b-a2a9-f8ec-6ba6-3f8e5ee89877Product name120140508
bc07ef78-e82d-0c19-31f4-31f263780582Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
84651-200-30IBTROZI30 in 1 BOTTLECAPSULE304
84651-200-90IBTROZI90 in 1 BOTTLECAPSULE904
84651-200-90IBTROZI1 in 1 CARTONCAPSULE14
84651-200-93IBTROZI3 in 1 CARTONCAPSULE34

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
84651-200-30EA - Each84651-200ffd26c79-b28f-49bb-9685-65abaecb117012025-07-08
84651-200-93EA - Each84651-200474b578e-68b2-4adc-9f19-33e52aa25d8412025-07-08

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
IBTROZITALETRECTINIBNuvation Bio Inc.51ac8e52-3269-4102-8dc8-dba22d82128c2026-09-21Warnings, Adverse reactionsExact identifier
application applno (NDA): 219713
application number: NDA219713
ndc (product): 84651-200

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
2716931IBTROZI 200 MG Oral CapsulePSN51ac8e52-3269-4102-8dc8-dba22d82128c4
2716925taletrectinib 200 MG Oral CapsulePSN51ac8e52-3269-4102-8dc8-dba22d82128c4
2716931taletrectinib 200 MG Oral Capsule [Ibtrozi]SBD51ac8e52-3269-4102-8dc8-dba22d82128c4
2716925taletrectinib 200 MG Oral CapsuleSCD51ac8e52-3269-4102-8dc8-dba22d82128c4
2716931Ibtrozi 200 MG (as taletrectinib adipate 272 MG) Oral CapsuleSY51ac8e52-3269-4102-8dc8-dba22d82128c4
2716925taletrectinib 200 MG (as taletrectinib adipate 272 MG) Oral CapsuleSY51ac8e52-3269-4102-8dc8-dba22d82128c4

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startSampleExclude flagStatus
84651-200-308465102003030 in 1 BOTTLEHistorical
84651-200-90846510200901 BOTTLE in 1 CARTON (84651-200-90) / 90 CAPSULE in 1 BOTTLE1 bottle2026-09-01NoNoCurrent
84651-200-93846510200933 BOTTLE in 1 CARTON (84651-200-93) / 30 CAPSULE in 1 BOTTLE (84651-200-30) 3 bottle2025-06-13NoNoCurrent